
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical Co is positioned favorably within the rapidly expanding global ophthalmic surgical device market, projected to reach $20.1 billion by 2025, reflecting a robust 2.9% compound annual growth rate since 2019. The company has demonstrated significant growth in the phakic intraocular lens (IOL) segment, with market share increasing from 14.3% in 2019 to an estimated 26.5% by 2025, underscoring its competitive edge and innovation in refractive surgery. Additionally, with an enhanced acquisition offer from Alcon, indicating increased recognition of Staar's value and growth potential, the company's operational advancements and strategic positioning further bolster a positive outlook.
Bears say
Staar Surgical has faced significant revenue declines, with a staggering drop of 82% YoY in China during 4Q’24 and continued adverse impacts into 2025, directly contributing to overall financial losses and heightened operational uncertainties. The company's EBITDA losses and cash consumption highlight its struggle to achieve the growth and margin expansion necessary for maintaining premium valuations, leaving the stock trading at a notable discount to historical multiples. Furthermore, the ongoing weakness in China's macroeconomic environment and increased competition may pose prolonged risks to recovery, with potential market revaluation reflecting lower growth expectations and heightened execution risks.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares